PL4021575T3 - Sposoby leczenia choroby cln2 u osobników pediatrycznych - Google Patents

Sposoby leczenia choroby cln2 u osobników pediatrycznych

Info

Publication number
PL4021575T3
PL4021575T3 PL20771408.0T PL20771408T PL4021575T3 PL 4021575 T3 PL4021575 T3 PL 4021575T3 PL 20771408 T PL20771408 T PL 20771408T PL 4021575 T3 PL4021575 T3 PL 4021575T3
Authority
PL
Poland
Prior art keywords
methods
pediatric subjects
cln2 disease
treating cln2
treating
Prior art date
Application number
PL20771408.0T
Other languages
English (en)
Inventor
David JACOBY
Joshua Henshaw
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of PL4021575T3 publication Critical patent/PL4021575T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL20771408.0T 2019-08-29 2020-08-31 Sposoby leczenia choroby cln2 u osobników pediatrycznych PL4021575T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893535P 2019-08-29 2019-08-29
PCT/US2020/048704 WO2021042020A1 (en) 2019-08-29 2020-08-31 Methods for treating cln2 disease in pediatric subjects

Publications (1)

Publication Number Publication Date
PL4021575T3 true PL4021575T3 (pl) 2024-09-23

Family

ID=72470612

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20771408.0T PL4021575T3 (pl) 2019-08-29 2020-08-31 Sposoby leczenia choroby cln2 u osobników pediatrycznych

Country Status (25)

Country Link
US (1) US20220273775A1 (pl)
EP (2) EP4021575B1 (pl)
JP (2) JP2022546042A (pl)
KR (1) KR20220054375A (pl)
CN (1) CN114828960A (pl)
AR (1) AR119871A1 (pl)
AU (1) AU2020336984A1 (pl)
BR (1) BR112022003598A2 (pl)
CA (1) CA3152521A1 (pl)
CL (1) CL2022000496A1 (pl)
DK (1) DK4021575T3 (pl)
ES (1) ES2987156T3 (pl)
FI (1) FI4021575T3 (pl)
HR (2) HRP20220370A1 (pl)
HU (1) HUE067135T2 (pl)
IL (1) IL290763A (pl)
LT (1) LT4021575T (pl)
MX (1) MX2022002451A (pl)
PL (1) PL4021575T3 (pl)
PT (1) PT4021575T (pl)
RS (1) RS65763B1 (pl)
SI (1) SI4021575T1 (pl)
SM (1) SMT202400315T1 (pl)
TW (1) TW202122106A (pl)
WO (1) WO2021042020A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303693B2 (en) * 2021-04-02 2025-05-20 Neuropace, Inc. Systems and methods for controlling operation of an implanted neurostimulation system based on a mapping of episode durations and seizure probability biomarkers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use
US20020006400A1 (en) * 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
LT2588130T (lt) * 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
SG11201803218PA (en) * 2015-10-23 2018-05-30 Univ Iowa Res Found Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
CA3117982A1 (en) * 2018-11-14 2020-05-22 Bhargavi KONDRAGUNTA Gene therapy for neuronal ceroid lipofuscinoses

Also Published As

Publication number Publication date
TW202122106A (zh) 2021-06-16
AR119871A1 (es) 2022-01-19
EP4021575B1 (en) 2024-05-22
RS65763B1 (sr) 2024-08-30
CL2022000496A1 (es) 2022-10-21
DK4021575T3 (da) 2024-08-05
WO2021042020A1 (en) 2021-03-04
CN114828960A (zh) 2022-07-29
ES2987156T3 (es) 2024-11-14
PT4021575T (pt) 2024-07-30
JP2022546042A (ja) 2022-11-02
AU2020336984A1 (en) 2022-03-10
KR20220054375A (ko) 2022-05-02
SI4021575T1 (sl) 2024-10-30
HRP20240871T1 (hr) 2024-10-11
EP4438120A3 (en) 2024-12-11
HRP20220370A1 (hr) 2022-09-16
BR112022003598A2 (pt) 2022-05-24
EP4021575A1 (en) 2022-07-06
EP4438120A2 (en) 2024-10-02
FI4021575T3 (fi) 2024-07-24
CA3152521A1 (en) 2021-03-04
JP2025165414A (ja) 2025-11-04
HUE067135T2 (hu) 2024-10-28
SMT202400315T1 (it) 2024-09-16
MX2022002451A (es) 2022-06-02
IL290763A (en) 2022-04-01
US20220273775A1 (en) 2022-09-01
LT4021575T (lt) 2024-08-12

Similar Documents

Publication Publication Date Title
EP3370617A4 (en) NON-INVASIVE ILLUSTRATION AND TREATMENT SYSTEM FOR CARDIAC ERRORS
IL288958A (en) Exosomes for the treatment of diseases
IL299024B2 (en) Tripeptidyl peptidase-1 preparations and methods for treating neuronal ceroid lipofuscinosis
GB2557382B (en) System and method for removing gibbs artifact in medical imaging system
SG11202006040YA (en) Intraoral imaging apparatus, medical apparatus, and program
IL262121A (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11202007420PA (en) Pediatric niraparib formulations and pediatric treatment methods
WO2015191934A8 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
LT3119911T (lt) Junginiai, skirti naudoti taikant alzheimerio ligos gydymo būdą apoe4+/+ pacientams
SG11202002348UA (en) Apparatus and method for non-invasively monitoring blood glucose
PT3600415T (pt) Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
AU2022271491B2 (en) Antisense oligonucleotides for use in treating alzheimer's disease
SG11202004292PA (en) Medicine for tissue regeneration, and preparation method therefor
PL3731893T3 (pl) Urządzenie do pozaustrojowego oczyszczania krwi
PL3254725T3 (pl) Urządzenie do leczenia naczyń krwionośnych w skórze
IL288677A (en) Methods for treating Fabry disease in patients with kidney failure
EP3606428A4 (en) METHOD AND APPARATUS FOR NON-INVASIVE MEASUREMENT OF CIRCULATORY HEMOGLOBIN
SI3307277T1 (sl) Enoverižni oligonukleotidi za uporabo pri zdravljenju motenj kože
EP3244816A4 (en) Apparatus and method for forming an opening in patient's tissue
SG11201912800RA (en) Hemofilter for in vivo blood filtration
EP3556388A4 (en) METHOD FOR PREVENTING AND TREATING PATHOLOGICAL KIDNEY DAMAGE
SI4021575T1 (sl) Metode za zdravljenje bolezni CLN2 pri prediatričnih subjektih
GB201910645D0 (en) Treatment for dry eye disease
GB201810277D0 (en) Skin treatment apparatus